Symbols / SRRK
SRRK Chart
About
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.80B |
| Enterprise Value | 4.54B | Income | -353.43M | Sales | — |
| Book/sh | 2.47 | Cash/sh | 3.62 | Dividend Yield | — |
| Payout | 0.00% | Employees | 128 | IPO | — |
| P/E | — | Forward P/E | -15.81 | PEG | — |
| P/S | — | P/B | 19.04 | P/C | — |
| EV/EBITDA | -12.59 | EV/Sales | — | Quick Ratio | 6.02 |
| Current Ratio | 6.30 | Debt/Eq | 44.93 | LT Debt/Eq | — |
| EPS (ttm) | -3.15 | EPS next Y | -2.97 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-03 | ROA | -76.61% |
| ROE | -218.04% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 102.01M |
| Shs Float | 77.45M | Short Float | 25.57% | Short Ratio | 15.08 |
| Short Interest | — | 52W High | 49.82 | 52W Low | 22.71 |
| Beta | 0.70 | Avg Volume | 1.14M | Volume | 450.30K |
| Target Price | $50.36 | Recom | Strong_buy | Prev Close | $47.01 |
| Price | $47.02 | Change | 0.02% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$50.36
Mean price target
2. Current target
$47.02
Latest analyst target
3. DCF / Fair value
$-25.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$47.02
Low
$42.00
High
$60.00
Mean
$50.36
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-26 | main | HC Wainwright & Co. | Buy → Buy | $58 |
| 2026-01-09 | init | Citigroup | — → Buy | $55 |
| 2026-01-07 | init | UBS | — → Buy | $60 |
| 2025-12-17 | main | Barclays | Overweight → Overweight | $52 |
| 2025-11-18 | init | Wolfe Research | — → Outperform | $42 |
| 2025-11-18 | main | JP Morgan | Overweight → Overweight | $47 |
| 2025-11-17 | main | Barclays | Overweight → Overweight | $45 |
| 2025-10-20 | main | Truist Securities | Buy → Buy | $44 |
| 2025-10-09 | init | B of A Securities | — → Buy | $53 |
| 2025-09-24 | main | Piper Sandler | Overweight → Overweight | $51 |
| 2025-09-24 | main | Barclays | Overweight → Overweight | $44 |
| 2025-09-23 | main | HC Wainwright & Co. | Buy → Buy | $44 |
| 2025-09-17 | init | Barclays | — → Overweight | $45 |
| 2025-08-07 | main | BMO Capital | Outperform → Outperform | $45 |
| 2025-07-17 | init | Cantor Fitzgerald | — → Overweight | — |
| 2024-11-26 | main | HC Wainwright & Co. | Buy → Buy | $50 |
| 2024-11-25 | main | Wedbush | Outperform → Outperform | $47 |
| 2024-11-25 | main | Truist Securities | Buy → Buy | $45 |
| 2024-11-12 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2024-10-15 | main | Piper Sandler | Overweight → Overweight | $42 |
- Is Scholar Rock Holding (SRRK) Attractive After Strong Multi Year Share Price Gains - simplywall.st Mon, 23 Feb 2026 19
- Assessing Scholar Rock (SRRK) Valuation After Recent Share Pullback And Conflicting P/B And DCF Signals - Yahoo Finance Singapore ue, 24 Feb 2026 02
- Junlin Ho Sells 9,580 Shares of Scholar Rock (NASDAQ:SRRK) Stock - MarketBeat hu, 19 Feb 2026 23
- Rare-disease drug developer Scholar Rock to stream three investor talks - Stock Titan Wed, 18 Feb 2026 13
- Scholar Rock Holding Corp. (SRRK) Stock Analysis: Biotech Innovator with Strong Buy Signals - DirectorsTalk Interviews Wed, 18 Feb 2026 02
- $SRRK stock is up 16% today. Here's what we see in our data. - Quiver Quantitative Fri, 14 Nov 2025 08
- Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire Fri, 14 Nov 2025 08
- Scholar Rock (SRRK) to Release Quarterly Earnings on Tuesday - MarketBeat ue, 24 Feb 2026 08
- Scholar Rock schedules March 3 call on 2025 financial results - Stock Titan ue, 10 Feb 2026 08
- Scholar Rock Holding (SRRK) Valuation Check After Strong Recent Share Price Momentum - Yahoo Finance Mon, 02 Feb 2026 08
- Scholar Rock Holding Corporation Stock (SRRK) Opinions on Insider Purchase and FDA Delay - Quiver Quantitative Wed, 08 Oct 2025 07
- Scholar Rock (NASDAQ:SRRK) Insider Sells $193,425.21 in Stock - MarketBeat hu, 19 Feb 2026 23
- Seven new Scholar Rock hires get 114,668 shares in inducement package - Stock Titan Fri, 13 Feb 2026 08
- Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses - Yahoo Finance Sun, 16 Nov 2025 08
- $SRRK stock is up 8% today. Here's what we see in our data. - Quiver Quantitative Fri, 26 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4157 | 193418 | — | Sale at price 46.53 per share. | MARANTZ JING L. | Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 9580 | 445740 | — | Sale at price 46.53 per share. | HO JUNLIN | General Counsel | — | 2026-02-17 00:00:00 | D |
| 2 | 9035 | 420382 | — | Sale at price 46.53 per share. | PARLAVECCHIO CARYN | Officer | — | 2026-02-17 00:00:00 | D |
| 3 | 7989 | 371714 | — | Sale at price 46.53 per share. | QATANANI MOHAMMED | Officer | — | 2026-02-17 00:00:00 | D |
| 4 | 128004 | — | — | Stock Award(Grant) at price 0.00 per share. | HALLAL DAVID L | Chief Executive Officer | — | 2026-02-09 00:00:00 | D |
| 5 | 47021 | — | — | Stock Award(Grant) at price 0.00 per share. | VAISHNAW AKSHAY K | Officer and Director | — | 2026-02-09 00:00:00 | D |
| 6 | 34482 | — | — | Stock Award(Grant) at price 0.00 per share. | MARANTZ JING L. | Officer | — | 2026-02-09 00:00:00 | D |
| 7 | 36572 | — | — | Stock Award(Grant) at price 0.00 per share. | HO JUNLIN | General Counsel | — | 2026-02-09 00:00:00 | D |
| 8 | 29258 | — | — | Stock Award(Grant) at price 0.00 per share. | PARLAVECCHIO CARYN | Officer | — | 2026-02-09 00:00:00 | D |
| 9 | 29258 | — | — | Stock Award(Grant) at price 0.00 per share. | QATANANI MOHAMMED | Officer | — | 2026-02-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -250.12M | -168.45M | -131.38M | -127.29M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -246.29M | -165.79M | -134.50M | -131.80M |
| ReconciledDepreciation | 1.94M | 2.84M | 2.99M | 2.63M |
| EBITDA | -250.12M | -168.45M | -131.38M | -127.29M |
| EBIT | -252.05M | -171.29M | -134.37M | -129.92M |
| NormalizedIncome | -246.29M | -165.79M | -134.50M | -131.80M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -246.29M | -165.79M | -134.50M | -131.80M |
| TotalExpenses | 252.05M | 171.29M | 167.56M | 148.74M |
| TotalOperatingIncomeAsReported | -252.05M | -171.29M | -134.37M | -129.92M |
| DilutedAverageShares | 99.84M | 83.35M | 59.61M | 36.71M |
| BasicAverageShares | 99.84M | 83.35M | 59.61M | 36.71M |
| DilutedEPS | -2.47 | -1.99 | -2.26 | -3.59 |
| BasicEPS | -2.47 | -1.99 | -2.26 | -3.59 |
| DilutedNIAvailtoComStockholders | -246.29M | -165.79M | -134.50M | -131.80M |
| NetIncomeCommonStockholders | -246.29M | -165.79M | -134.50M | -131.80M |
| NetIncome | -246.29M | -165.79M | -134.50M | -131.80M |
| NetIncomeIncludingNoncontrollingInterests | -246.29M | -165.79M | -134.50M | -131.80M |
| NetIncomeContinuousOperations | -246.29M | -165.79M | -134.50M | -131.80M |
| PretaxIncome | -246.29M | -165.79M | -134.50M | -131.80M |
| OtherIncomeExpense | 5.76M | 5.51M | -132.00K | -1.88M |
| OtherNonOperatingIncomeExpenses | 5.76M | 5.51M | -132.00K | -1.88M |
| OperatingIncome | -252.05M | -171.29M | -134.37M | -129.92M |
| OperatingExpense | 252.05M | 171.29M | 167.56M | 148.74M |
| ResearchAndDevelopment | 184.55M | 121.90M | 124.44M | 108.47M |
| SellingGeneralAndAdministration | 67.50M | 49.40M | 43.12M | 40.27M |
| GeneralAndAdministrativeExpense | 67.50M | 49.40M | 43.12M | 40.27M |
| OtherGandA | 67.50M | 49.40M | 43.12M | 40.27M |
| TotalRevenue | 0.00 | 0.00 | 33.19M | 18.82M |
| OperatingRevenue | 0.00 | 0.00 | 33.19M | 18.82M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 93.82M | 75.98M | 51.67M | 35.21M |
| ShareIssued | 93.82M | 75.98M | 51.67M | 35.21M |
| TotalDebt | 65.13M | 61.82M | 69.40M | 77.06M |
| TangibleBookValue | 368.63M | 225.22M | 260.24M | 172.07M |
| InvestedCapital | 418.78M | 275.24M | 309.98M | 222.07M |
| WorkingCapital | 404.23M | 255.45M | 291.63M | 201.02M |
| NetTangibleAssets | 368.63M | 225.22M | 260.24M | 172.07M |
| CapitalLeaseObligations | 14.98M | 11.80M | 19.65M | 27.06M |
| CommonStockEquity | 368.63M | 225.22M | 260.24M | 172.07M |
| TotalCapitalization | 418.78M | 273.90M | 309.98M | 220.50M |
| TotalEquityGrossMinorityInterest | 368.63M | 225.22M | 260.24M | 172.07M |
| StockholdersEquity | 368.63M | 225.22M | 260.24M | 172.07M |
| GainsLossesNotAffectingRetainedEarnings | 160.00K | 92.00K | -884.00K | -35.00K |
| OtherEquityAdjustments | 160.00K | 92.00K | -884.00K | -35.00K |
| RetainedEarnings | -922.72M | -676.42M | -510.63M | -376.13M |
| AdditionalPaidInCapital | 1.29B | 901.47M | 771.70M | 548.20M |
| CapitalStock | 94.00K | 76.00K | 52.00K | 35.00K |
| CommonStock | 94.00K | 76.00K | 52.00K | 35.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 106.29M | 85.82M | 97.93M | 132.37M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 59.35M | 53.08M | 61.54M | 68.07M |
| LongTermDebtAndCapitalLeaseObligation | 59.35M | 53.08M | 61.54M | 68.07M |
| LongTermCapitalLeaseObligation | 9.21M | 4.39M | 11.80M | 19.65M |
| LongTermDebt | 50.15M | 48.68M | 49.74M | 48.42M |
| CurrentLiabilities | 46.94M | 32.74M | 36.39M | 64.30M |
| OtherCurrentLiabilities | 85.00K | 222.00K | 230.00K | |
| CurrentDeferredLiabilities | 0.00 | 33.19M | ||
| CurrentDeferredRevenue | 0.00 | 33.19M | ||
| CurrentDebtAndCapitalLeaseObligation | 5.77M | 8.74M | 7.85M | 8.98M |
| CurrentCapitalLeaseObligation | 5.77M | 7.41M | 7.85M | 7.41M |
| CurrentDebt | 1.33M | 1.58M | ||
| OtherCurrentBorrowings | 1.33M | 1.58M | ||
| PayablesAndAccruedExpenses | 41.16M | 23.91M | 28.32M | 21.89M |
| CurrentAccruedExpenses | 31.07M | 20.45M | 24.32M | 17.46M |
| Payables | 10.10M | 3.46M | 3.99M | 4.43M |
| OtherPayable | 24.00K | |||
| AccountsPayable | 10.10M | 3.46M | 3.99M | 4.43M |
| TotalAssets | 474.92M | 311.04M | 358.17M | 304.44M |
| TotalNonCurrentAssets | 23.76M | 22.84M | 30.14M | 39.13M |
| OtherNonCurrentAssets | 2.41M | 2.41M | 4.22M | 4.12M |
| NonCurrentPrepaidAssets | 2.94M | 4.42M | ||
| GoodwillAndOtherIntangibleAssets | 2.40M | 4.07M | ||
| OtherIntangibleAssets | 2.40M | 4.07M | ||
| NetPPE | 18.41M | 16.02M | 25.93M | 35.01M |
| AccumulatedDepreciation | -13.22M | -11.33M | -10.23M | -7.29M |
| GrossPPE | 31.62M | 27.34M | 36.16M | 42.30M |
| Leases | 3.61M | 3.58M | 5.16M | 5.16M |
| ConstructionInProgress | 0.00 | 48.00K | ||
| OtherProperties | 25.95M | 21.69M | 28.84M | 34.94M |
| MachineryFurnitureEquipment | 2.06M | 2.08M | 2.16M | 2.15M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 451.17M | 288.19M | 328.02M | 265.32M |
| OtherCurrentAssets | 12.66M | 12.32M | ||
| PrepaidAssets | 11.74M | 7.18M | 9.93M | 12.32M |
| Receivables | 2.15M | 1.08M | 2.73M | |
| OtherReceivables | 2.15M | 1.08M | 2.73M | |
| CashCashEquivalentsAndShortTermInvestments | 437.28M | 279.94M | 315.36M | 252.99M |
| OtherShortTermInvestments | 259.40M | 178.08M | 212.09M | 40.16M |
| CashAndCashEquivalents | 177.88M | 101.86M | 103.28M | 212.84M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -201.05M | -145.30M | -133.76M | -132.04M |
| RepaymentOfDebt | 0.00 | -975.00K | 0.00 | |
| IssuanceOfDebt | 0.00 | 24.98M | ||
| IssuanceOfCapitalStock | 324.41M | 97.71M | 195.31M | 13.10M |
| CapitalExpenditure | -98.00K | -71.00K | -1.06M | -5.25M |
| InterestPaidSupplementalData | 6.62M | 6.40M | 4.37M | 2.08M |
| EndCashPosition | 180.28M | 104.26M | 105.77M | 215.33M |
| BeginningCashPosition | 104.26M | 105.77M | 215.33M | 162.86M |
| ChangesInCash | 76.02M | -1.51M | -109.56M | 52.48M |
| FinancingCashFlow | 353.03M | 102.57M | 194.83M | 44.95M |
| CashFlowFromContinuingFinancingActivities | 353.03M | 102.57M | 194.83M | 44.95M |
| NetOtherFinancingCharges | -125.00K | 3.00K | -975.00K | -20.00K |
| ProceedsFromStockOptionExercised | 28.74M | 4.86M | 492.00K | 6.89M |
| NetCommonStockIssuance | 324.41M | 97.71M | 195.31M | 13.10M |
| CommonStockIssuance | 324.41M | 97.71M | 195.31M | 13.10M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 24.98M | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | 24.98M | |
| LongTermDebtPayments | 0.00 | -975.00K | 0.00 | |
| LongTermDebtIssuance | 0.00 | 24.98M | ||
| InvestingCashFlow | -76.06M | 41.14M | -171.70M | 134.31M |
| CashFlowFromContinuingInvestingActivities | -76.06M | 41.14M | -171.70M | 134.31M |
| NetInvestmentPurchaseAndSale | -75.96M | 41.20M | -170.63M | 139.56M |
| SaleOfInvestment | 217.20M | 332.00M | 130.00M | 200.00M |
| PurchaseOfInvestment | -293.16M | -290.80M | -300.63M | -60.44M |
| NetPPEPurchaseAndSale | -98.00K | -58.00K | -1.06M | -5.25M |
| SaleOfPPE | 0.00 | 13.00K | 0.00 | |
| PurchaseOfPPE | -98.00K | -71.00K | -1.06M | -5.25M |
| OperatingCashFlow | -200.95M | -145.23M | -132.69M | -126.79M |
| CashFlowFromContinuingOperatingActivities | -200.95M | -145.23M | -132.69M | -126.79M |
| ChangeInWorkingCapital | 6.59M | -10.61M | -34.39M | -28.44M |
| ChangeInOtherWorkingCapital | -33.19M | -18.82M | ||
| ChangeInOtherCurrentLiabilities | -6.38M | -7.99M | -7.42M | -5.17M |
| ChangeInOtherCurrentAssets | 1.47M | -2.70M | -97.00K | -601.00K |
| ChangeInPayablesAndAccruedExpense | 17.28M | -4.46M | 6.64M | 4.68M |
| ChangeInAccruedExpense | 10.65M | -3.93M | 6.89M | 3.66M |
| ChangeInPayable | 6.63M | -529.00K | -251.00K | 1.02M |
| ChangeInAccountPayable | 6.63M | -529.00K | -251.00K | 1.02M |
| ChangeInPrepaidAssets | -5.77M | 4.53M | -322.00K | -8.53M |
| ChangeInReceivables | 0.00 | |||
| ChangesInAccountReceivables | 0.00 | |||
| OtherNonCashItems | 5.48M | 7.40M | 7.62M | 6.73M |
| StockBasedCompensation | 36.63M | 27.14M | 27.70M | 23.15M |
| AmortizationOfSecurities | -5.29M | -6.22M | -2.14M | 918.00K |
| DepreciationAmortizationDepletion | 1.94M | 2.84M | 2.99M | 2.63M |
| DepreciationAndAmortization | 1.94M | 2.84M | 2.99M | 2.63M |
| OperatingGainsLosses | 11.00K | 33.00K | 24.00K | |
| GainLossOnSaleOfPPE | 0.00 | 11.00K | 33.00K | 24.00K |
| NetIncomeFromContinuingOperations | -246.29M | -165.79M | -134.50M | -131.80M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SRRK
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|